GlassScriptPhysician profile
Blaine Wajdowicz
NPI 1639604853
$3,189.10
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $1,545 · 2023: $998 · 2024: $34.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,316.82 | 2021-2023 | Cabenuva, Apretude, Dovato |
| Gilead Sciences, INC. | $1,136.64 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $266.01 | 2021-2023 | Delstrigo, Pifeltro |
| Janssen Scientific Affairs, LLC | $127.25 | 2021-2023 | Symtuza |
| Abbvie INC. | $87.57 | 2022-2024 | |
| Uswm, LLC | $78.24 | 2023 | Lucemyra, Zimhi |
| Janssen Biotech, INC. | $72.73 | 2021-2022 | |
| Lilly USA, LLC | $27.08 | 2021 | |
| Alkermes, INC. | $25.84 | 2023 | Vivitrol |
| Biohaven Pharmaceuticals, INC. | $25.75 | 2021 | |
| Braeburn INC. | $25.17 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blaine Wajdowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.